These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 17635895)

  • 21. The importance of physicians identifying and reporting adverse drug events.
    Gatti JC
    Am Fam Physician; 2012 Feb; 85(4):318. PubMed ID: 22335311
    [No Abstract]   [Full Text] [Related]  

  • 22. Drug Manufacturers' Delayed Disclosure of Serious and Unexpected Adverse Events to the US Food and Drug Administration.
    Ma P; Marinovic I; Karaca-Mandic P
    JAMA Intern Med; 2015 Sep; 175(9):1565-6. PubMed ID: 26214395
    [No Abstract]   [Full Text] [Related]  

  • 23. Triptans and serious adverse vascular events: data mining of the FDA Adverse Event Reporting System database.
    Roberto G; Piccinni C; D'Alessandro R; Poluzzi E
    Cephalalgia; 2014 Jan; 34(1):5-13. PubMed ID: 23921799
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Automatic detection of adverse events to predict drug label changes using text and data mining techniques.
    Gurulingappa H; Toldo L; Rajput AM; Kors JA; Taweel A; Tayrouz Y
    Pharmacoepidemiol Drug Saf; 2013 Nov; 22(11):1189-94. PubMed ID: 23935003
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacoepidemiological characterization of drug-induced adverse reaction clusters towards understanding of their mechanisms.
    Mizutani S; Noro Y; Kotera M; Goto S
    Comput Biol Chem; 2014 Jun; 50():50-9. PubMed ID: 24534381
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Report slams US FDA's drug safety reform efforts.
    Bristol N
    Lancet; 2007 Mar; 369(9567):1072. PubMed ID: 17405202
    [No Abstract]   [Full Text] [Related]  

  • 27. Evaluating the completeness and accuracy of MedWatch data.
    Getz KA; Stergiopoulos S; Kaitin KI
    Am J Ther; 2014; 21(6):442-6. PubMed ID: 23011177
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adverse drug reactions (ADRs) in children: Part 1.
    Kanneh AB
    Paediatr Nurs; 2004; 16(6):32-5. PubMed ID: 15328727
    [No Abstract]   [Full Text] [Related]  

  • 29. Utilization of chi-square statistics for screening adverse drug-drug interactions in spontaneous reporting systems.
    Gosho M; Maruo K; Tada K; Hirakawa A
    Eur J Clin Pharmacol; 2017 Jun; 73(6):779-786. PubMed ID: 28280890
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety concerns at the FDA.
    Lancet; 2005 Feb 26-Mar 4; 365(9461):727-8. PubMed ID: 15733696
    [No Abstract]   [Full Text] [Related]  

  • 31. Experts call for active surveillance of drug safety.
    Wadman M
    Nature; 2007 Mar; 446(7134):358-9. PubMed ID: 17377551
    [No Abstract]   [Full Text] [Related]  

  • 32. Patterns in spontaneous adverse event reporting among branded and generic antiepileptic drugs.
    Bohn J; Kortepeter C; Muñoz M; Simms K; Montenegro S; Dal Pan G
    Clin Pharmacol Ther; 2015 May; 97(5):508-17. PubMed ID: 25670505
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The FDA drug safety surveillance program: adverse event reporting trends.
    Weiss-Smith S; Deshpande G; Chung S; Gogolak V
    Arch Intern Med; 2011 Mar; 171(6):591-3. PubMed ID: 21444854
    [No Abstract]   [Full Text] [Related]  

  • 34. Processing and evaluation of adverse drug experience reports at the Food and Drug Administration Center for Veterinary Medicine.
    Keller WC; Bataller N; Oeller DS
    J Am Vet Med Assoc; 1998 Jul; 213(2):208-11. PubMed ID: 9676589
    [No Abstract]   [Full Text] [Related]  

  • 35. Assessing the extent and impact of the masking effect of disproportionality analyses on two spontaneous reporting systems databases.
    Maignen F; Hauben M; Hung E; Van Holle L; Dogne JM
    Pharmacoepidemiol Drug Saf; 2014 Feb; 23(2):195-207. PubMed ID: 24243665
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacoepidemiology and its input to pharmacovigilance.
    Faillie JL; Montastruc F; Montastruc JL; Pariente A
    Therapie; 2016 Apr; 71(2):211-6. PubMed ID: 27080840
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Physician reporting of adverse drug reactions. Results of the Rhode Island Adverse Drug Reaction Reporting Project.
    Scott HD; Thacher-Renshaw A; Rosenbaum SE; Waters WJ; Green M; Andrews LG; Faich GA
    JAMA; 1990 Apr; 263(13):1785-8. PubMed ID: 2313850
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A 6-year retrospective study of adverse drug reactions due to drug-drug interactions between nervous system drugs.
    Shi QP; He XD; Yu ML; Zhu JX; Liu Y; Ding F; Sang R; Jiang XD; Zhang SQ
    Int J Clin Pharmacol Ther; 2014 May; 52(5):392-401. PubMed ID: 24691061
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 150 years of pharmacovigilance.
    Routledge P
    Lancet; 1998 Apr; 351(9110):1200-1. PubMed ID: 9643710
    [No Abstract]   [Full Text] [Related]  

  • 40. The role of litigation in defining drug risks.
    Kesselheim AS; Avorn J
    JAMA; 2007 Jan; 297(3):308-11. PubMed ID: 17227983
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.